US20160095885A1 - Induction Medium & Methods for Stem Cell Culture & Therapy - Google Patents

Induction Medium & Methods for Stem Cell Culture & Therapy Download PDF

Info

Publication number
US20160095885A1
US20160095885A1 US14/504,399 US201414504399A US2016095885A1 US 20160095885 A1 US20160095885 A1 US 20160095885A1 US 201414504399 A US201414504399 A US 201414504399A US 2016095885 A1 US2016095885 A1 US 2016095885A1
Authority
US
United States
Prior art keywords
tlr
ligand
stem cells
hypoxia
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/504,399
Other languages
English (en)
Inventor
Aline BETANCOURT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanbio Inc
Original Assignee
Commence Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commence Bio Inc filed Critical Commence Bio Inc
Priority to US14/504,399 priority Critical patent/US20160095885A1/en
Priority to US14/720,603 priority patent/US9321994B1/en
Assigned to WibiWorks Therapeutics, Inc. reassignment WibiWorks Therapeutics, Inc. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BETANCOURT, Aline
Priority to JP2017516783A priority patent/JP6890538B2/ja
Priority to KR1020207016164A priority patent/KR102275640B1/ko
Priority to AU2015324241A priority patent/AU2015324241B2/en
Priority to RU2017114574A priority patent/RU2717983C2/ru
Priority to EP23169770.7A priority patent/EP4234032A3/en
Priority to KR1020217030644A priority patent/KR102342470B1/ko
Priority to KR1020227031764A priority patent/KR102542748B1/ko
Priority to CN201580065072.7A priority patent/CN107002029A/zh
Priority to CA3000334A priority patent/CA3000334C/en
Priority to CA3210154A priority patent/CA3210154A1/en
Priority to KR1020217020769A priority patent/KR102316952B1/ko
Priority to KR1020217041459A priority patent/KR102445071B1/ko
Priority to ES15847382T priority patent/ES2961691T3/es
Priority to MX2017004288A priority patent/MX2017004288A/es
Priority to KR1020237030185A priority patent/KR102636786B1/ko
Priority to KR1020247004511A priority patent/KR102766202B1/ko
Priority to KR1020177011391A priority patent/KR102163403B1/ko
Priority to PCT/US2015/052029 priority patent/WO2016053758A1/en
Priority to KR1020257003641A priority patent/KR20250023596A/ko
Priority to EP15847382.7A priority patent/EP3201318B1/en
Priority to KR1020237019063A priority patent/KR102576875B1/ko
Assigned to COMMENCE BIO, INC. reassignment COMMENCE BIO, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: WibiWorks Therapeutics, Inc.
Priority to US15/072,943 priority patent/US20160194602A1/en
Priority to US15/072,971 priority patent/US10273449B2/en
Publication of US20160095885A1 publication Critical patent/US20160095885A1/en
Priority to US16/001,300 priority patent/US11046929B2/en
Assigned to SANBIO, INC. reassignment SANBIO, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COMMENCE BIO, INC.
Priority to US17/096,559 priority patent/US20210062140A1/en
Priority to AU2021201433A priority patent/AU2021201433C1/en
Priority to JP2021068586A priority patent/JP7672867B2/ja
Priority to JP2023077664A priority patent/JP7773502B2/ja
Priority to AU2023203680A priority patent/AU2023203680B2/en
Priority to JP2025091622A priority patent/JP2025131663A/ja
Priority to AU2025238026A priority patent/AU2025238026A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0043—Medium free of human- or animal-derived components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/92—Medium free of human- or animal-derived components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/052—Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2313—Interleukin-13 (IL-13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/58—Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Definitions

  • the invention provides novel stem-cell culture and therapy methods and culture medium.
  • compositions for the purpose of inducing, activating, or priming discrete uniform cell phenotypes to selectively promote or suppress inflammation and immunity providing significant advantages over known culture media and methods, yielding primed, activated, or induced cells used in cell-based therapy.
  • the invention can be used to provide more uniform and predictable ex-vivo expanded and induced, primed, or activated populations of MSC stem cells, which can be used for cell-based therapy. There is a long-felt need in the art for an improved method to provide a uniform and efficacious large number of stem cells required for cell-based therapy.
  • An advantage of the various embodiments of the invention is that they can be used to induce, activate or prime cultures of multipotent stem cells into uniform and discrete phenotypes that behave in a predictable manner upon introduction into a patient.
  • MSCs stem cells mesenchymal stem cells, marrow stromal cells, multipotent stromal cells, multipotent stem cells—derived from various adult tissues.
  • Clinical applications of MSCs require reproducible cell culture methods and cell expansion methods that provide adequate numbers of cells of suitable quality and consistent therapeutic benefits. Different culture media and methods have had varying degrees of success.
  • further improvements to MSC culture media and methods that ensures expanded yields of primed, activated, or induced cells used in cell-based therapy having safe and consistently reproducible therapeutic effects.
  • TLRs Toll-like receptors
  • Toll-like receptors recognize “danger” signals, and their activation leads to profound cellular and systemic responses that mobilize innate and adaptive host immune cells.
  • the danger signals that trigger TLRs are released following most tissue pathologies. Since danger signals recruit immune cells to sites of injury, the Inventor reasoned that MSCs might be recruited in a similar way.
  • MSCs express several TLRs (e.g., TLR3 and TLR4, known in the art), and that their migration, invasion, and secretion of immune modulating factors is drastically affected by specific TLR-agonist engagement,
  • TLR3 and TLR4 known in the art
  • the Inventor observed diverse consequences to the MSCs following stimulation of TLR3 when compared to TLR4 by as low-level, short-term TLR-priming protocol.
  • the Inventor proposed a new paradigm for MSCs that took its cue from the monocyte literature. Specifically, that MSCs can be polarized (induced, activated, or primed) by downstream TLR signaling into two homogenously acting phenotypes classified as MSC1 and MSC2.
  • TLR primed MSCs or MSC1
  • TLR3-primed MSCs or MSC2
  • PBMCs peripheral blood mononuclear cells
  • MSCs into the pro-immune MSC1 phenotype by TLR4 activation or into the anti-inflammatory MSC2 phenotype by TLR3 activation ensures uniform and defined cells that solves an industry hurdle by providing defined and predictable cells for use in cell-based therapy applications.
  • Erythropoietin also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or red.
  • Hood cell production It is a cytokine or cell-signaling molecule for erythrocyte (red blood cell) precursors in the bone marrow, Human EPO has a molecular weight of 34 kDa and is also called hematopoietin or hemopoietin.
  • EPO is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and tubular epithelial tubule and in perisinusoidal cells in the liver. While liver production predominates early in development (fetal and perinatal period), the kidney is the predominant EPO production site in adults.
  • erythropoietin In addition to erythropoiesis, erythropoietin also has other known biological functions. For example, it plays an important role in the brain's response to neuronal injury by providing a pro-survival anti-apoptosis (programmed cell death) signal. EPO is also involved in the wound healing process. Synthetic erythropoietin is also produced by recombinant DNA technology in cell culture. Additionally, several different pharmaceutical EPO-like agents are available with a variety of glycosylation patterns, and are collectively called erythropoiesis-stimulating agents (ESA). EPO is used in this invention as a means to prevent premature cell death and prolong survival of the yielded primed, activated, or induced cells used in cell-based therapy.
  • ESA erythropoiesis-stimulating agents
  • Consistent oxygen supply is an important factor influencing all major aspects of cell biology including survival, proliferation, differentiation, and migration.
  • mammalian cells (not stem cells) require a consistent supply of oxygen to maintain a robust energy production, and to preserve normal cell function and cell survival.
  • mammalian stem cells seem to thrive and persist in the hypoxic environment with oxygen tension ranging from 0.5% to 7%) of the bone marrow.
  • oxygen tension ranging from 0.5% to 7%
  • stem cell means a cell which is capable of giving rise to multiple different types of cells.
  • meenchymal stem cell or “MSC” means a stem cell originally derived from the mesenchyme. The term refers to a cell which is capable of differentiating into at least two or more of an osteoblast, a chondrocyte, an adipocyte, or a myocyte.
  • MSCs may be isolated from any type of adult tissue. Typically MSCs are isolated from bone marrow, adipose tissue, umbilical cord, or peripheral blood, in a preferred aspect of the invention, MSCs are obtained from bone marrow or lipoaspirates, themselves obtained from adipose tissue.
  • multipotent and alternative term “pluripotent” mean a cell which is capable of giving rise to multiple types of cells of different tissue lineages.
  • cellular therapy or “cell-based therapy” means the transplantation of human or animal cells to prevent, treat, or ameliorate one or more symptoms associated with a disease or disorder, such as, but not limited to, the replacement or repair of damaged tissues or organs, the modulation of immune reactions and the reduction of inflammatory symptoms and cancers.
  • subject refers to an animal, preferably a mammal including non-primates (e.g., cow, pig, horse, cat, dog, rat, or mouse) or a primate (e g, as monkey, or a human). In as preferred embodiment, the subject is a human.
  • non-primates e.g., cow, pig, horse, cat, dog, rat, or mouse
  • a primate e g, as monkey, or a human.
  • the subject is a human.
  • treat when used directly in reference to a patient or subject mean the amelioration of one or more symptoms associated with a disorder including, but not limited to, an inflammatory disorder, an autoimmune disease or an immunologically mediated disease including rejection of transplanted organs and tissues, where the amelioration results from the administration of the immunomodulatory cells yielded by the invention, or a pharmaceutical composition comprising immunomodulatory cells yielded by the invention, to a subject in need of such treatment.
  • a disorder including, but not limited to, an inflammatory disorder, an autoimmune disease or an immunologically mediated disease including rejection of transplanted organs and tissues, where the amelioration results from the administration of the immunomodulatory cells yielded by the invention, or a pharmaceutical composition comprising immunomodulatory cells yielded by the invention, to a subject in need of such treatment.
  • repair when used directly in reference to damaged tissues means the amelioration. of such damage by both. direct mechanisms such as the regeneration of damaged tissues, as well as through indirect mechanisms, e.g., reducing inflammation thereby enabling tissue formation.
  • Allogenic means from different individuals of the same species, When individuals possess genes that differ at one or more loci, they are said to be allogenic. In contrast, “autologous” means from the same individual.
  • immune disease refers to as condition in a subject characterized by cellular, tissue and/or organ injury caused by an immunological reaction of the subject.
  • autoimmune disease refers to a condition in a subject characterized by cellular, tissue and/or organ injury caused by an immunological reaction of the subject to its own cells, tissues, and/or organs.
  • autoimmune diseases which can be treated with the immunomodulatory cells yielded by the invention include alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune diseases of the adrenal gland, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune oophoritis and orchitis, autoimmune thrombocytopenia, Behcet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue- dermatitis, chronic fatigue immune dysfunction syndrome (CMS), chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatrical pemphigoid, CREST syndrome, cold agglutinin disease, discoid l
  • Immuno disorders include autoimmune diseases and immunologically mediated diseases.
  • Immuno mediated inflammatory disease means any disease characterized by chronic or acute inflammation, resulting from, associated with, or triggered by, a dysregulation of the normal immune response; Crohn's disease, type 1 diabetes mellitus, rheumatoid arthritis, inflammatory bowel disease, psoriasis, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, Hashimoto's disease, graft-versus-host disease, Sjogren's syndrome, pernicious anemia, Addison disease, scleroderma, Goodpasture's syndrome, ulcerative colitis, autoimmune hemolytic anemia, sterility, myasthenia gravis, multiple sclerosis, Basedow's disease, thrombopenia purpura, Guillain-Barre syndrome, allergy, asthma, atopic disease, arteriosclerosis, myocarditis, cardiomyopathy, glomerular nephritis, hypoplastic anemia, and rejection
  • immunomodulatory refers to the modification, amplification, inhibition or reduction of one or more biological activities of the immune system which includes, but is not limited to, downregulation of immune response, augmentation of immune responses and changes of the inflammatory states mediated by changes in cytokine profile, cytotoxic activity and antibody production and their effects on immune and immune related cells.
  • inflammatory disorders refers to a condition in a subject characterized by inflammation, chronic inflammation.
  • Illustrative, non-limiting examples of inflammatory disorders include, but are not limited to, Celiac Disease, rheumatoid arthritis (R), Inflammatory Bowel Disease (IBD), asthma, encephalitis, chronic obstructive pulmonary disease (COPD), inflammatory osteolysis, allergic disorders, septic shock, pulmonary fibrosis (e.g., idiopathic pulmonary fibrosis), inflammatory vacultides (e.g., polyarteritis nodosa, Wegner's granulomatosis, Takayasu's arteritis, temporal arteritis, and lymphomatoid granulomatosus), post-traumatic vascular angioplasty (e.g., restenosis after angioplasty), undifferentiated spondyloarthropathy, undifferentiated arthropathy, arthritis, inflammatory osteolysis, chronic hepatitis,
  • isolated cell population means a cell population, isolated from the human or animal body, which is substantially free of one or more other cell populations that are normally associated with the cell population in vivo or in vitro.
  • ligand inducer means an agent or agents that result in increased production of such a ligand.
  • a ligand inducer for a Toll-like receptor (TLR) ligand will yield increased TLR ligand, and is therefore essentially equivalent to the TLR ligand itself.
  • TLR Toll-like receptor
  • MHC major histocompatibility complex
  • HLA human leukocyte antigen
  • population of cells means any number of cells greater than 1, but is preferably at least 1 ⁇ 10 cells, at least 1 ⁇ 10 cells, at least 1 ⁇ 10 cells, at least 1 ⁇ 10 6 6 cells, at least 1 ⁇ 10 7 cells, at least 1 ⁇ 10 8 cells, or at least 1 ⁇ 10 9 cells.
  • At least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94% or at least 95%, of the stem cells (% by cell number) in an initial cell population will be undifferentiated MSCs.
  • a cell surface marker means that, in a cell population, more than 20%, preferably more than 30%, 40%, 50%, 60%, 70%, 80%, 90% 95%, 98%, 99%, or even 100% of the cells express the cell surface marker.
  • Expression of cell surface markers may be determined, for example, by means of flow cytometry for as specific cell surface marker using conventional methods and apparatus (for example a BECKMAN COULTER EPICS XL FAGS system used with commercially available antibodies and standard protocols known in the art) that show a signal for a specific cell surface marker in flow cytometry above the background signal using conventional methods and apparatus.
  • the background signal is defined as the signal intensity given by a non-specific antibody of the same isotype as the specific antibody used to detect each surface marker in conventional FAGS analysis.
  • the specific signal observed is stronger than 20%, preferably stronger than, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 500%, 1000%, 5000%, 10000% or above, than the background signal intensity using conventional methods and apparatus.
  • commercially available and known monoclonal antibodies against said cell-surface markers e.g., cellular receptors and transmembrane proteins
  • the invention provides an inducing, activating, or priming culture induction medium for a population of multipotent stem cells (MSCs), comprising a Toll-like receptor (TLR) ligand or TLR-ligand inducer in combination with erythropoietin (EPO) and with exposure to hypoxia (preferably 0.5-2% oxygen) or hypoxia mimetic (preferably cobalt chloride or desferrioxamine), plus additional, standard components of cell-culture media known in the art and described here.
  • TLR Toll-like receptor
  • EPO erythropoietin
  • hypoxia mimetic preferably cobalt chloride or desferrioxamine
  • the invention also provides a culture-medium induction supplement comprising a Toll-like receptor (TLR) ligand or TLR-ligand inducer in combination with erythropoietin (EPO) and with exposure to hypoxia hypoxia mimetic, which can be added to other, existing culture media.
  • TLR Toll-like receptor
  • EPO erythropoietin
  • a supplement might be appropriate where unusual components or concentrations of other components are appropriate for certain circumstances.
  • the invention also provides a hermetically-sealed culture vessel containing the culture induction medium or culture-medium induction supplement of the invention.
  • the invention also provides a method for preparing a culture induction medium as disclosed herein, comprising the steps of: (a) obtaining a culture medium; and (b) adding a Toll-like receptor (TLR) ligand or TLR-ligand inducer in combination with erythropoietin (EPO) and with exposure to hypoxia (0.5-2% oxygen) or hypoxia mimetic (cobalt chloride or desferrioxamine) to the culture medium.
  • TLR Toll-like receptor
  • EPO erythropoietin
  • hypoxia mimetic cobalt chloride or desferrioxamine
  • the invention also provides a composition comprising: (a) a culture medium according to the invention; and (b) stem cells.
  • the invention also provides a composition containing: (a) a culture medium according to the invention; and (b) a solid surface.
  • the invention also provides the use of a culture medium of the invention for inducing, activating or priming a population of multipotent stem cells.
  • the invention also provides an ex-vivo method for inducing, activating or priming a population of multipotent stem cells, comprising: (a) providing a population of multipotent stem cells; (b) providing a culture medium of the invention; (c) contacting the stem cells with the culture medium; and (d) culturing the cells under appropriate conditions.
  • the invention provides the use of a Toll-like receptor (TLR) ligand or TLR-ligand inducer in combination with erythropoietin and with exposure to hypoxia (0.5-2% oxygen) or hypoxia mimetic (cobalt chloride or desferrioxainine) in the manufacture of a cellular therapy medicament.
  • TLR Toll-like receptor
  • the invention also provides a method of manufacture of a cellular therapy medicament, comprising: (a) providing a population of multipotent stem cells; (b) providing a culture medium of the invention; (c) contacting the stem cells with the culture medium; and (d) culturing the cells under appropriate conditions.
  • the invention also provides the use of a composition comprising: (a) a culture medium according to the invention; and (b) stem cells, for manufacturing a cellular therapy medicament.
  • the invention also provides the use of a composition comprising (a) a culture medium according to the invention; and (b) a solid surface, for manufacturing a cellular therapy medicament.
  • a cellular therapy medicament of the invention comprises a prophylactically or therapeutically effective amount of stem cells and a pharmaceutical carrier.
  • stem cells of mesenchymal origin most preferably bone marrow-derived stem cells.
  • Suitable pharmaceutical carriers are known in the art and are preferably those approved by a regulatory agency of the US Federal or a state government or listed in the U S Pharmacopeia, or European Pharmacopeia, or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
  • carrier refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic agent is administered.
  • the composition if desired, can also contain minor amounts of pH buffering agents. Examples of suitable pharmaceutical carriers are described in “Remington's Pharmaceutical Sciences” by E W Martin.
  • compositions will contain a prophylactically or therapeutically effective amount of a prophylactic or therapeutic agent preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the subject,
  • the formulation should suit the mode of administration.
  • the medicaments are sterile and in suitable form for administration to a subject, preferably an animal subject, more preferably a mammalian subject, and most preferably a human subject.
  • the medicament of the invention may be in a variety of forms, These include, for example, semi-solid, and liquid dosage forms, such as lyophilized preparations, liquid solutions or suspensions, injectable and infusible solutions, etc., the medicament is preferably injectable.
  • the medicaments are for treating or repairing damaged tissue (preferably mesenchymal tissue), and/or for the treatment, modulation, prophylaxis, and/or amelioration of one or more symptoms associated with inflammatory and/or immune disorders.
  • the methods and cells of the invention are of use in the treatment of any disorder characterized by either or all of said symptoms.
  • a representative non-exhaustive list of such disorders is provided in the definitions section, Particularly preferred is a medicament for the treatment of immune-mediated inflammatory diseases, Further preferred is a medicament for the treatment of diabetes mellitus, rheumatoid arthritis (R), inflammatory bowel disease (IBD, including Crohn's disease and/or Ulcerative Colitis) and multiple sclerosis (MS).
  • R rheumatoid arthritis
  • IBD inflammatory bowel disease
  • MS multiple sclerosis
  • the invention also provides the use of a Toll-like receptor (TLR) ligand or TLR-ligand inducer in combination with erythropoietin and with exposure to hypoxia (0.5-2% oxygen) or hypoxia mimetic (cobalt chloride or desferrioxamine) for multipotent stem cell culture.
  • TLR Toll-like receptor
  • hypoxia 0.5-2% oxygen
  • hypoxia mimetic cobalt chloride or desferrioxamine
  • the specific ingredients and ratio of ingredients of the culture media, supplements and compositions of the invention can vary according to particular needs and applications. Likewise, the precise steps of the methods of the invention can vary according to particular needs and applications.
  • the culture media, supplements, methods, compositions and uses according to this invention may be optimised by routine experimentation.
  • a desired outcome is an anti-inflammatory therapeutic effect
  • a culture medium, supplement or composition will specifically contain a TLR3 ligand or TLR-ligand inducer in combination with erythropoietin and with exposure to hypoxia (0.5-2% oxygen) or hypoxia mimetic (cobalt chloride or desferrioxamine)
  • hypoxia 0.5-2% oxygen
  • hypoxia mimetic cobalt chloride or desferrioxamine
  • a pro-immune therapeutic effect if a culture medium, supplement or composition will specifically contain a TLR4 ligand or TLR-ligand inducer in combination with erythropoietin and with exposure to hypoxia (0.5-2% oxygen) or hypoxia mimetic (cobalt chloride or desferrioxamine).
  • the amount of each of the ingredients described herein can be optimised independently of the other ingredients by routine optimisation or one or more ingredients can be added or removed.
  • a culture medium can he tested for its ability to support induction, activation or priming of multipotent stem cells by testing it alongside or in place of a known culture medium or method. The culture media, supplements, methods, compositions and uses of the invention are described in more detail below.
  • the induction media of the invention comprises a Toll-like receptor (TLR) ligand or TLR-ligand inducer in combination with erythropoietin and with exposure to hypoxia (0.5-2% oxygen) or hypoxia mimetic (cobalt chloride or desferrioxamine).
  • TLR Toll-like receptor
  • the induction media of the invention comprises a Toll-like receptor (TLR) ligand or TLR-ligand inducer.
  • the induction media of the invention comprises erythropoietin and exposure to hypoxia (0.5-2% oxygen) or hypoxia mimetic (cobalt chloride or desfiffrioxamine).
  • the induction media of the invention comprises a Toll-like receptor (TLR) ligand or TLR-ligand inducer in combination with erythropoietin and with exposure to hypoxia 0.5-2% oxygen) or hypoxia mimetic (cobalt chloride or desferrioxamine).
  • TLR Toll-like receptor
  • hypoxia mimetic cobalt chloride or desferrioxamine
  • the induction media of the invention may comprise two or more, three or more, 4-, 5-,6-, 7-,8-,9-, 1.0- or more, combinations of a Toll-like receptor (TLR) ligand or TLR-ligand inducer in combination with erythropoietin (EPO) and with exposure to hypoxia (0.5-2% oxygen) or hypoxia mimetic (cobalt chloride or desferrioxamine).
  • TLR Toll-like receptor
  • EPO erythropoietin
  • hypoxia mimetic cobalt chloride or desferrioxamine
  • An induction medium of the invention may comprise between about 0.10 picomolar (pM) and about 100 millimolar (mM) of a TLR ligand or TLR-ligand inducer in combination with about 0.5 mU/mL and about 50 erythropoietin (EPO) and with exposure to about 0.5 to about 2% oxygen conditions (hypoxia) or hypoxia mimetic such as cobalt chloride or desferrioxamine, at a concentration of about 10 micromolar to about 1 mM, or any other combination of the above TLR ligand or TLR-ligand inducer, erythropoietin, and hypoxia.
  • pM picomolar
  • mM millimolar
  • EPO erythropoietin
  • hypoxia mimetic such as cobalt chloride or desferrioxamine
  • Cell induction media typically contain a large number of ingredients, which are necessary to support maintenance of the cultured cells.
  • An induction medium of the invention will therefore normally contain many other ingredients in addition to a Toll-like receptor (TLR) ligand or TLR-ligand inducer in combination with erythropoietin and with exposure to hypoxia (0.5-2% oxygen) or hypoxia mimetic (cobalt chloride or desferrioxamine).
  • TLR Toll-like receptor
  • TLR-ligand or TLR-ligand inducer in combination with erythropoietin and with exposure to hypoxia (0.5-2% oxygen) or hypoxia mimetic (cobalt chloride or desferrioxamine).
  • Suitable combinations of ingredients can readily be formulated by the skilled person, taking into account the following disclosure.
  • An induction medium according to the invention will generally be a nutrient solution comprising standard cell culture ingredients, such as amino acids, vitamins, trace metals, inorganic salts, a carbon energy source, and a
  • An induction medium of the invention may contain serum. Serum contains cellular and non-cellular factors and components that may be necessary for viability and expansion. Serum obtained from any appropriate source may be used, including fetal bovine serum (FIBS), bovine serum (BS), calf serum (CS), fetal calf serum (FCS), newborn calf serum (NCS), goat serum (GS), horse serum (HS), porcine serum, sheep serum, rabbit serum, rat serum (RS), etc. It is also within the scope of the invention that if said MSC are of human origin, the cell induction medium is supplemented with a human serum, preferably of autologous origin. It is understood that sera can he heat inactivated at 55-65 deg. C if deemed necessary to inactivate components of the complement cascade. Where a serum replacement is used, it may be used at between about 2% and about 40% by volume of the medium, according to conventional techniques.
  • FIBS fetal bovine serum
  • BS bovine serum
  • CS calf serum
  • an induction medium of the invention may contain a serum replacement.
  • serum replacement formulations are commercially available and are known to the skilled person, such as but not limited to serum albumin, serum transferrin, selenium, and recombinant proteins including but not limited to insulin, platelet-derived growth factor (PDGF), and basic fibroblast. growth factor (bFGF).
  • PDGF platelet-derived growth factor
  • bFGF basic fibroblast. growth factor
  • an induction medium of the invention may be serum-free and/or serum replacement-free.
  • a serum-free medium is one that contains no animal serum of any type, Serum-free media may be preferred to avoid possible xeno-contamination of the stem cells.
  • A. serum replacement-free medium is one that has not been supplemented with any commercial serum replacement formulation.
  • An induction medium of the invention will normally he formulated in deionized, distilled water, An induction medium of the invention will typically be sterilized prior to use to prevent contamination, e.g. by ultraviolet light, heating, irradiation or filtration.
  • the induction medium may be frozen (e.g. at ⁇ 20° C. or ⁇ 80° C.) for storage or transport.
  • Antimicrobial agents are also typically used in media to mitigate bacterial, mycoplasmal, and fungal contamination.
  • the medium may contain one or more antimicrobial agents or antibiotics to prevent contamination.
  • antibiotics or anti-mycotic compounds used are mixtures of penicillin/streptomycin, but can also include, but are not limited to amphotericin (Fungizone®), ampicilhn, gentamicin, Neomycin, hygromacin, kanamycin, mitomycin, etc.
  • the culture medium is a medium that has been conditioned by the addition of cells induced by a Toll-like receptor (TLR) ligand or TLR-ligand inducer in combination with erythropoietin and with exposure to hypoxia (0.5-2% oxygen) or hypoxia mimetic (cobalt chloride or desferrioxamine).
  • TLR Toll-like receptor
  • Conditioned medium is produced by culturing a population of said cells in a induction medium for a time sufficient to condition the medium, then harvesting the conditioned medium.
  • the medium may be conditioned on mammalian cells, e.g. mouse cells or human cells.
  • mammalian cells e.g. mouse cells or human cells.
  • mammalian cells e.g. mouse cells or human cells.
  • An induction medium may be a 1 ⁇ formulation or a concentrated formulation, e.g. a 2 ⁇ to 250 ⁇ concentrated medium formulation.
  • a 1 ⁇ formulation each ingredient in the medium is at the concentration intended for cell induction.
  • a concentrated formulation one or more of the ingredients is present at a higher concentration than intended for cell induction.
  • Induction medium can be concentrated using known methods e.g. salt precipitation or selective filtration.
  • a concentrated medium may be diluted for use with water (preferably deionized and distilled) or any appropriate solution, e.g. an aqueous saline solution, an aqueous buffer or a culture medium.
  • An induction medium as disclosed herein may be capable of inducing, activating or priming a population of stem cells in a multipotent, undifferentiated and proliferative state for only a single passage or population doubling under appropriate conditions.
  • Stem cells are considered to be in a multipotent, undifferentiated and proliferative state if they exhibit certain characteristics as described in more detail elsewhere herein, Appropriate conditions can be selected by die skilled person from those normally used for multipotent stem cell culture.
  • the invention also provides a hermetically-sealed vessel containing an induction medium of the invention.
  • Hermetically-sealed vessels may be preferred for transport or storage of the induction media, to prevent contamination.
  • the vessel may be any suitable vessel, such as a bioreactor, a flask, a plate, a bottle, a jar, a vial or a bag.
  • the invention also provides a method for preparing an induction medium, comprising the steps of: (a) obtaining a culture medium; and (b) adding a Toll-like receptor (TLR) ligand or TLR-ligand inducer in combination with erythropoietin (EPO) and with exposure to hypoxia (0.5-2% oxygen) or hypoxia mimetic (cobalt chloride or desferrioxamine) to the culture medium.
  • TLR Toll-like receptor
  • EPO erythropoietin
  • hypoxia mimetic cobalt chloride or desferrioxamine
  • a method for preparing a induction medium may comprise the steps of (a) obtaining a culture medium; and (b) adding a TLR ligand or TLR-ligand inducer in combination with erythropoietin (EPO) and with exposure to hypoxia (0.5-2% oxygen) or hypoxia mimetic (cobalt chloride or desferrioxamine) to the culture medium.
  • a method for preparing an induction medium may comprise the steps of: (a) obtaining a culture medium; and (b) adding a TLR ligand, EPO and cobalt chloride to the culture medium.
  • the induction media of the invention can be used to induce, activate or prime a population of multipotent stem cells. Accordingly, the invention provides the use of any induction medium as disclosed herein for inducing, activating or priming a population of multipotent stem cells into discrete uniform phenotypes for cell-based therapy.
  • the invention also provides an ex-vivo method for inducing, activating or priming a population of multipotent stem cells, comprising: (a) providing a population of multipotent stem cells; (b) providing a induction medium as disclosed herein; (c) contacting the stem cells with the induction medium; and (d) culturing the stem cells under appropriate conditions,
  • the invention also provides a method cellular therapy, comprising: (a) providing a population of multipotent stem cells; (b) providing an induction medium of the invention; (c) contacting the stem cell population with the induction medium; and (d) culturing the cells under appropriate conditions.
  • the methods of the invention may comprise culturing the cells in contact with a solid surface as described elsewhere herein.
  • the invention provides a method comprising; (a) providing a population of multipotent stem cells; (b) providing an induction medium as disclosed herein; (c) contacting the stem cells with the induction medium; and (d) culturing the cells under appropriate conditions and in contact with a solid surface.
  • the invention also provides the use of an induction medium as disclosed herein and a solid surface to expand a population of multipotent stem cells.
  • the multipotent stem cells may adhere, attach or be seeded onto said support.
  • the cells are plated at a desired density such as between about 100 cells/cm2 to about 100,000 cells/cm2 (such as about 500 cells/cm2 to about 50,000 cells/cm2, or, more particularly, between about 1,000 cells/cm2 to about 20,000 cells/cm2) prior to inducing, activating or priming of the stem cells,
  • the cell density is between 200-10,000 cells/cm2.
  • the steps of the methods disclosed herein can be performed in any suitable order or at the same time, as appropriate, and need not he performed in the order in which they are listed,
  • the step of providing a population of multipotent stem cells may be performed before, after or at the same time as, the step of providing an induction medium.
  • the methods and uses of the invention may involve any induction medium or supplement as described herein. Accordingly, in some embodiments the methods of the invention may be serum and /or serum replacement-free methods. In some embodiments, the methods of the invention may be used to induce cells in the absence of contact with a layer of feeder cells.
  • the preferred methods and uses of the invention are for the inducing, activating or priming of the population of multipotent stem cells to occur once the cells have been expanded and prior to being cryopreserved and used in cell-based therapy.
  • said stem cell population is of adult origin, and it is further preferred that said cells are a mesenchymal stem cell population, as in bone marrow derived or adipose tissue-derived cells.
  • Conditions for the culture of stein cells are known to the person skilled in the art. It is preferred that the culture is carried out in the presence of a solid support suitable for the adherence of mesenchymal stem cells.
  • Said method of manufacture may optionally further comprise the steps of: (a) passaging the cells into a culture medium as disclosed herein; (b) further culturing the cells under appropriate conditions and (c) inducing, activating or priming the cells.
  • ex vivo expansion of the MSC without inducing differentiation can he accomplished for extended time periods for example by using specially screened lots of suitable serum (such as fetal bovine serum or human serum). Methods for measuring viability and yield are known in the art (e,g., trypan blue exclusion).
  • any of the steps and procedures for isolating the cells of the cell population of the invention can be performed manually, if desired.
  • the process of isolating such cells can be facilitated and/or automated through one or more suitable devices, examples of which are known in the art.
  • Cell culture vessels of various shapes and sizes (e.g. flasks, single or multiwell plates, single or multiwell dishes, bottles, jars, vials, bags, bioreactors) and constructed from various different materials (e.g. plastic, glass) are known in the art.
  • a suitable cell culture vessel can readily be selected by the skilled person.
  • the invention also provides a culture-medium induction supplement that can he used to produce a culture induction medium as disclosed here.
  • a “culture-medium induction supplement’ is a mixture of ingredients that cannot itself support multipotent stem cells, but which enables or improves multipotent stem cell culture when combined with other cell culture-medium ingredients.
  • the supplement can therefore be used to produce a functional cell culture medium of the invention by combining it with other cell culture ingredients to produce an appropriate medium formulation.
  • culture medium supplements is well known in the art.
  • the invention provides a culture-medium induction supplement that comprises adding a TLR ligand or TLR-ligand inducer in combination with erythropoietin (EPO) and with exposure to hypoxia (0.5-2% oxygen) or hypoxia mimetic (cobalt chloride or desferrioxamine).
  • EPO erythropoietin
  • the supplement may contain any ligands disclosed herein.
  • the supplement may also contain one or more additional cell culture ingredients, e.g. one or more cell culture ingredients selected from the group consisting of amino acids, vitamins, inorganic salts, trace elements, carbon energy sources and buffers.
  • a culture-medium induction supplement may be a concentrated liquid supplement (e.g., a 2 ⁇ to 250 ⁇ concentrated liquid supplement) or may be a dry supplement. Both liquid and dry types of supplements are well known in the art.
  • a supplement may be lyophilized.
  • a culture-medium induction supplement of the invention will typically be sterilized prior to use to prevent contamination, e.g., by ultraviolet light, heating, irradiation or filtration.
  • a culture-medium induction supplement may be frozen (e.g. at ⁇ 20° C., or ⁇ 80° C.) for storage or transport.
  • the invention also provides a hermetically-sealed vessel containing a culture medium supplement of the invention.
  • Hermetically-sealed vessels may be preferred for transport or storage of the culture media supplements disclosed herein, to prevent contamination,
  • the vessel may he any suitable vessel, such as a bioreactor, a flask, a plate, a bottle, a jar, a vial, or a bag.
  • the solid surface comprises plastic but may alternatively comprise of glass, extracellular matrix.
  • the surface may be planar, tubular, or in the form of a scaffold, head or fibre.
  • compositions of the invention may comprise serum, or may be serum-free and/or serum-replacement free, as described elsewhere herein.
  • Multipotent stem cells are those that have the potential to differentiate into cells of all three germ layers (endoderm, mesoderm and ectoderm) under appropriate conditions. Multipotent stem cells are not totipotent, i.e. they cannot form an entire organism, such as a foetus. Multipotent stem cells for use in the invention can be obtained using well-known methods (see below). It is envisaged that various types of multipotent stem cells may be used in conjunction with the invention, whether obtained from embryonic, foetal, or adult tissue but are preferably derived from adult tissue sources.
  • the induction media disclosed herein may be used to culture mammalian stem cells, particularly human adult stem cells, Human adult stem cells that may be used in conjunction with the invention are preferably mesenchymal stem cells. Mouse or primate stem cells may also be used. In preferred embodiments, the stem cells are human bone marrow-derived stein cells (MSC).
  • MSC human bone marrow-derived stein cells
  • Multipotent stem cells may he identified by their ability to differentiate into cells of all three germ layers e.g. by determining the ability of the cells to differentiate into cells showing detectable expression of markers specific for all three germ layers. References in the singular (e.g. to “a cell” and equivalent references) encompass the plural (e.g. “cells”) unless the context requires otherwise.
  • the induction media of the invention can be used to induce, activate or prime a population of multipotent stem cells. Accordingly, the invention provides the use of any induction medium as disclosed herein for inducing, activating or priming a population of multipotent stem cells into discrete uniform phenotypes for cell-based therapy. These discrete and uniform phenotypes can be an anti-inflammatory MSC phenotype (MSC2), and a uniform and discrete pro-immune anti-tumor MSC phenotype (MSC1).
  • MSC2 anti-inflammatory MSC phenotype
  • MSC1 uniform and discrete pro-immune anti-tumor MSC phenotype
  • the preferred method of induction for a uniform and discrete anti-inflammatory MSC phenotype is incubation of the MSC with a culture medium containing a Toll-like receptor-3 (TLR3) ligand such as polyinosinic:polycytidylic acid (or poly(I:C); 1 ⁇ g/mL) combination with erythropoietin (1 mU/mL or 5 ng/mL) and with exposure to hypoxia (1% oxygen) or hypoxia mimetic (cobalt chloride or desferrioxamine, either at 200 ⁇ M) for 1 hour upon 70-90% confluent growth.
  • TLR3 Toll-like receptor-3
  • the preferred method of induction for a uniform and discrete pro-immune anti-tumor MSC phenotype is incubation of the MSC with a culture medium containing a Toll-like receptor-4 (TLR4) ligand such as lipopolysaccharide (LPS, endotoxin at 10 ng/mL) combination with erythropoletin(1 mU/mL, or 5 ng/mL) and with exposure to hypoxia (1% oxygen) or hypoxia mimetic (cobalt chloride or desferrioxamine, either at 200 ⁇ M) for 1 hour upon 70-90% confluent growth.
  • TLR4 Toll-like receptor-4
  • TLR-ligands in combination with erythropoietin and with exposure to hypoxia (0.5-2% oxygen) or hypoxia mimetic (cobalt chloride desferrioxamine) are added to fresh culture medium, or as a culture supplement and incubated with the cells for 1 hr. Following this induction step, the MSC are washed twice in culture medium or suitable buffered saline solution without the TLR-ligands to remove cell and culture debris.
  • the induced, activated, or primed MSC can be harvested by traditional methods e.g.-trypsin and EDTA for between 5 seconds and 15 minutes at 37° C. or with a trypsin substitute (e.g. TrypLE from invitrogen), collagenase, dispase, accutase or other reagents known to the person skilled in the art.
  • a trypsin substitute e.g. TrypLE from invitrogen
  • the primed, activated, or induced MSC can be cryopreserved by standard methods.
  • the TLR3 ligand used in the induction culture medium may be IL4, IL13, poly(A:U), poly(I:C), and combinations thereof, and may be delivered by incubation, transfection, transduction, by carrier molecules, or by combinations thereof.
  • the TLR3 ligand or agonist is poly(I:C).
  • the TLR4 ligand used in the induction culture medium may be aminoalkyl glucosaminide 4-phosphates, interferons, TNF-alpha, GM-CSF, lipopolysaccharide (LPS), and combinations thereof, and may be delivered by incubation, transfection, transduction, by carrier molecules, or by combinations thereof.
  • the TLR4 ligand or agonist is LPS.
  • TLR3 agonist or TLR4 agonists may be delivered by incubation, transfection, transduction by carrier molecules, or by other techniques known to those of ordinary skill in the art.
  • the TLR3 ligand or agonist may be provided in an amount from about 10 pg/mL to about 100 ⁇ g/mL, from about 100 pg/mL to about 100 ⁇ g/mL, from about 1 ng/mL to about 100 ⁇ g/mL, from about 5 ng/mL to about 100 ⁇ g/mL, from about 10 ng/mL, to about 100 ⁇ g/mL, from about 100 ng/mL to about 100 ⁇ g/mL, from about 0.1 ⁇ g/mL to about 50 ⁇ g/mL, from about 0.1 ⁇ g/mL to about 10 ⁇ g/mL, from about 0.25 ⁇ g/mL to about 7.5 ⁇ g/mL, from about 0.5 ⁇ g/mL to about 5 ⁇ g/mL, from about 1 ⁇ g/mL to about 2.5 ⁇ g/mL, and preferably from about 1 ⁇ g/mL to about 1.5 ⁇ g/mL in culture medium or supplement as
  • the TLR4 ligand or agonist may be provided in an amount from about 10 pg/mL to about 10 ⁇ g/mL, from about 100 pg/mL to about 10 ⁇ g/mL, from about 1 ng/mL to about 1 ⁇ g/mL, from about 5 ng/mL to about 1 ⁇ g/mL, from about 10 ng/mL to about 1 ⁇ g/mL, from about 100 ng/mL to about 1 ⁇ g/mL, preferably from about 5 ng/mL to about 50 ng/mL, and also preferably from about 5 ng/mL to about 25 ng/mL in culture medium or supplement as noted above.
  • the cells may be incubated with TLR ligand or agonist ligand in combination with erythropoietin (EPO) and with exposure to hypoxia (0.5-2% oxygen) or hypoxia mimetic (cobalt chloride or desferrioxamine) for from about 1 minute to about 480 minutes, from about 5 minutes to about 475 minutes, from about 10 minutes to about 470 minutes, from about 15 minutes to about 400 minutes, from about 20 minutes to about 120 minutes, from about 25 minutes to about 90 minutes, from about 30 minutes to about 80 minutes, from about 35 minutes to about 70 minutes, from about 40 minutes to about 65 minutes, from about 45 minutes to about 60 minutes, from about 55 minutes to about 60 minutes, and preferably about 60 minutes.
  • EPO erythropoietin
  • hypoxia mimetic cobalt chloride or desferrioxamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
US14/504,399 2014-10-01 2014-10-01 Induction Medium & Methods for Stem Cell Culture & Therapy Abandoned US20160095885A1 (en)

Priority Applications (33)

Application Number Priority Date Filing Date Title
US14/504,399 US20160095885A1 (en) 2014-10-01 2014-10-01 Induction Medium & Methods for Stem Cell Culture & Therapy
US14/720,603 US9321994B1 (en) 2014-10-01 2015-05-22 Induction medium and methods for stem cell culture and therapy
KR1020237019063A KR102576875B1 (ko) 2014-10-01 2015-09-24 줄기 세포 배양을 위한 유도 배지 및 방법 및 요법
KR1020237030185A KR102636786B1 (ko) 2014-10-01 2015-09-24 줄기 세포 배양을 위한 유도 배지 및 방법 및 요법
PCT/US2015/052029 WO2016053758A1 (en) 2014-10-01 2015-09-24 Induction medium and methods for stem cell culture and therapy
AU2015324241A AU2015324241B2 (en) 2014-10-01 2015-09-24 Induction medium and methods for stem cell culture and therapy
RU2017114574A RU2717983C2 (ru) 2014-10-01 2015-09-24 Индукционная среда и способы культивирования стволовых клеток и терапии
EP23169770.7A EP4234032A3 (en) 2014-10-01 2015-09-24 Induction medium and methods for stem cell culture and therapy
KR1020217030644A KR102342470B1 (ko) 2014-10-01 2015-09-24 줄기 세포 배양을 위한 유도 배지 및 방법 및 요법
KR1020227031764A KR102542748B1 (ko) 2014-10-01 2015-09-24 줄기 세포 배양을 위한 유도 배지 및 방법 및 요법
CN201580065072.7A CN107002029A (zh) 2014-10-01 2015-09-24 用于干细胞培养和治疗的诱导培养基和方法
CA3000334A CA3000334C (en) 2014-10-01 2015-09-24 Induction medium and methods for stem cell culture and therapy
CA3210154A CA3210154A1 (en) 2014-10-01 2015-09-24 Induction medium and methods for stem cell culture and therapy
KR1020217020769A KR102316952B1 (ko) 2014-10-01 2015-09-24 줄기 세포 배양을 위한 유도 배지 및 방법 및 요법
KR1020217041459A KR102445071B1 (ko) 2014-10-01 2015-09-24 줄기 세포 배양을 위한 유도 배지 및 방법 및 요법
ES15847382T ES2961691T3 (es) 2014-10-01 2015-09-24 Medio de inducción y procedimientos para el cultivo y la terapia de células madre
MX2017004288A MX2017004288A (es) 2014-10-01 2015-09-24 Medio de induccion y metodos para el cultivo de y terapias con celulas madre.
JP2017516783A JP6890538B2 (ja) 2014-10-01 2015-09-24 幹細胞培養および療法のための誘導培地および方法
KR1020247004511A KR102766202B1 (ko) 2014-10-01 2015-09-24 줄기 세포 배양을 위한 유도 배지 및 방법 및 요법
KR1020177011391A KR102163403B1 (ko) 2014-10-01 2015-09-24 줄기 세포 배양을 위한 유도 배지 및 방법 및 요법
KR1020207016164A KR102275640B1 (ko) 2014-10-01 2015-09-24 줄기 세포 배양을 위한 유도 배지 및 방법 및 요법
KR1020257003641A KR20250023596A (ko) 2014-10-01 2015-09-24 줄기 세포 배양을 위한 유도 배지 및 방법 및 요법
EP15847382.7A EP3201318B1 (en) 2014-10-01 2015-09-24 Induction medium and methods for stem cell culture and therapy
US15/072,971 US10273449B2 (en) 2014-10-01 2016-03-17 Induction medium and methods for stem cell culture and therapy
US15/072,943 US20160194602A1 (en) 2014-10-01 2016-03-17 Induction Medium and Methods for Stem Cell Culture and Therapy
US16/001,300 US11046929B2 (en) 2014-10-01 2018-06-06 Induction medium and methods for stem cell culture and therapy
US17/096,559 US20210062140A1 (en) 2014-10-01 2020-11-12 Induction medium and methods for stem cell culture and therapy
AU2021201433A AU2021201433C1 (en) 2014-10-01 2021-03-05 Induction medium and methods for stem cell culture and therapy
JP2021068586A JP7672867B2 (ja) 2014-10-01 2021-04-14 幹細胞培養および療法のための誘導培地および方法
JP2023077664A JP7773502B2 (ja) 2014-10-01 2023-05-10 幹細胞培養および療法のための誘導培地および方法
AU2023203680A AU2023203680B2 (en) 2014-10-01 2023-06-13 Induction medium and methods for stem cell culture and therapy
JP2025091622A JP2025131663A (ja) 2014-10-01 2025-06-02 幹細胞培養および療法のための誘導培地および方法
AU2025238026A AU2025238026A1 (en) 2014-10-01 2025-09-25 Induction medium and methods for stem cell culture and therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/504,399 US20160095885A1 (en) 2014-10-01 2014-10-01 Induction Medium & Methods for Stem Cell Culture & Therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/720,603 Continuation US9321994B1 (en) 2014-10-01 2015-05-22 Induction medium and methods for stem cell culture and therapy

Publications (1)

Publication Number Publication Date
US20160095885A1 true US20160095885A1 (en) 2016-04-07

Family

ID=55631287

Family Applications (6)

Application Number Title Priority Date Filing Date
US14/504,399 Abandoned US20160095885A1 (en) 2014-10-01 2014-10-01 Induction Medium & Methods for Stem Cell Culture & Therapy
US14/720,603 Active US9321994B1 (en) 2014-10-01 2015-05-22 Induction medium and methods for stem cell culture and therapy
US15/072,971 Active US10273449B2 (en) 2014-10-01 2016-03-17 Induction medium and methods for stem cell culture and therapy
US15/072,943 Abandoned US20160194602A1 (en) 2014-10-01 2016-03-17 Induction Medium and Methods for Stem Cell Culture and Therapy
US16/001,300 Active 2034-11-13 US11046929B2 (en) 2014-10-01 2018-06-06 Induction medium and methods for stem cell culture and therapy
US17/096,559 Pending US20210062140A1 (en) 2014-10-01 2020-11-12 Induction medium and methods for stem cell culture and therapy

Family Applications After (5)

Application Number Title Priority Date Filing Date
US14/720,603 Active US9321994B1 (en) 2014-10-01 2015-05-22 Induction medium and methods for stem cell culture and therapy
US15/072,971 Active US10273449B2 (en) 2014-10-01 2016-03-17 Induction medium and methods for stem cell culture and therapy
US15/072,943 Abandoned US20160194602A1 (en) 2014-10-01 2016-03-17 Induction Medium and Methods for Stem Cell Culture and Therapy
US16/001,300 Active 2034-11-13 US11046929B2 (en) 2014-10-01 2018-06-06 Induction medium and methods for stem cell culture and therapy
US17/096,559 Pending US20210062140A1 (en) 2014-10-01 2020-11-12 Induction medium and methods for stem cell culture and therapy

Country Status (11)

Country Link
US (6) US20160095885A1 (enExample)
EP (2) EP4234032A3 (enExample)
JP (4) JP6890538B2 (enExample)
KR (10) KR102636786B1 (enExample)
CN (1) CN107002029A (enExample)
AU (4) AU2015324241B2 (enExample)
CA (2) CA3210154A1 (enExample)
ES (1) ES2961691T3 (enExample)
MX (1) MX2017004288A (enExample)
RU (1) RU2717983C2 (enExample)
WO (1) WO2016053758A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210113625A1 (en) * 2018-06-11 2021-04-22 Health And Biotech France (H & B France) Extracellular vesicles derived from mesenchymal stem cells

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160095885A1 (en) 2014-10-01 2016-04-07 WibiWorks Therapeutics, Inc. Induction Medium & Methods for Stem Cell Culture & Therapy
JP7168448B2 (ja) 2015-12-07 2022-11-09 コロラド ステート ユニバーシティー リサーチ ファウンデーション 感染創傷のための活性化幹細胞を含む組成物
CA3019574C (en) * 2016-03-31 2025-09-23 Sanbio Inc Medium, methods, cells and secreted factors for stem cell culture and therapy
WO2018067925A1 (en) * 2016-10-06 2018-04-12 Transgenex Nanobiotech, Inc. Methods for cancer stem cell (csc) expansion
CN110121553A (zh) * 2016-10-27 2019-08-13 纽约哥伦比亚大学董事会 免疫抑制性间充质细胞及其形成方法
JP7237301B2 (ja) * 2016-12-16 2023-03-13 有限会社大阪空気機械サービス 組織治癒剤
WO2020045399A1 (ja) * 2018-08-29 2020-03-05 株式会社Ｒｅｇｅｎｅ Ｐｈａｒｍ がんの治療のための医薬組成物
MX2021004924A (es) 2018-10-30 2021-08-16 Vitabolus Inc Administracion oral de celulas terapeuticas de mamiferos.
WO2021007180A1 (en) * 2019-07-05 2021-01-14 Case Western Reserve University Priming media and methods for stem cell culture and therapy
US20230257713A1 (en) * 2020-07-16 2023-08-17 Shanghai Jiaotong University Immunotherapy method of targeted chemokine and cytokine delivery by mesenchymal stem cell
KR102460408B1 (ko) * 2020-07-23 2022-10-28 포항공과대학교 산학협력단 줄기세포 시트를 제조하는 방법
TWI888659B (zh) * 2021-10-13 2025-07-01 芯芮生技開發股份有限公司 幹細胞條件培養基於製備抑制癌症組成物的用途
KR20250076941A (ko) * 2023-11-23 2025-05-30 (주) 넥셀 인간 전분화능 줄기세포 유래 심장 오가노이드를 이용해 허혈-재관류 손상에 의해 성체 급성 심근경색 및 심부전 질환이 유도된 체외 질환 모사 모델 제조 방법 및 이를 통해 제조된 체외 질환 모사 모델

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855510B2 (en) * 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
EP2298861B1 (en) 2004-03-22 2017-09-13 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
WO2005113751A1 (en) 2004-05-14 2005-12-01 Becton, Dickinson And Company Cell culture environments for the serum-free expansion of mesenchymal stem cells
WO2007136673A2 (en) 2006-05-19 2007-11-29 Medistem Laboratories, Inc. Treatment of disc degenerative disease and compositions for same
WO2009114860A2 (en) 2008-03-14 2009-09-17 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for the prevention and repair of inflammatory states
DK2285951T3 (en) 2008-05-28 2018-10-22 Univ Ramot TREATMENT OF CNS DISEASES OF CNS DISEASES
CN101407790B (zh) * 2008-10-30 2010-09-29 浙江大学 一种增强人骨髓间充质干细胞旁分泌能力的处理方法
WO2011068792A2 (en) * 2009-12-01 2011-06-09 The Regents Of The University Of California Compositions and methods for making and using bone marrow mesenchymal stem cells and erythroid progenitor cells
WO2012051210A2 (en) 2010-10-11 2012-04-19 The Administrators Of The Tulane Educational Fund Mesenchymal stem cells and related therapies
US8785190B2 (en) 2011-04-06 2014-07-22 Sanbio, Inc. Methods and compositions for modulating peripheral immune function
WO2012150707A1 (ja) 2011-05-02 2012-11-08 国立大学法人熊本大学 幹細胞からインスリン産生細胞への分化誘導を促進する低分子化合物および該化合物を用いた幹細胞からインスリン産生細胞への分化誘導方法
KR102108245B1 (ko) * 2011-11-30 2020-05-08 아스텔라스 인스티튜트 포 리제너러티브 메디슨 중간엽 간질 세포 및 이에 관련된 용도
EP2872619B1 (en) * 2012-07-11 2018-02-14 Imstem Biotechnology Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
US20160095885A1 (en) 2014-10-01 2016-04-07 WibiWorks Therapeutics, Inc. Induction Medium & Methods for Stem Cell Culture & Therapy
CN104845933A (zh) * 2015-05-15 2015-08-19 大连理工大学 一种增强脂肪间充质干细胞免疫学性能和迁移能力的方法
CA3019574C (en) 2016-03-31 2025-09-23 Sanbio Inc Medium, methods, cells and secreted factors for stem cell culture and therapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210113625A1 (en) * 2018-06-11 2021-04-22 Health And Biotech France (H & B France) Extracellular vesicles derived from mesenchymal stem cells

Also Published As

Publication number Publication date
KR20240024322A (ko) 2024-02-23
AU2023203680B2 (en) 2025-11-20
US10273449B2 (en) 2019-04-30
RU2717983C2 (ru) 2020-03-27
US20160097038A1 (en) 2016-04-07
RU2017114574A3 (enExample) 2019-04-17
KR20250023596A (ko) 2025-02-18
AU2023203680A1 (en) 2023-07-06
US20160201036A1 (en) 2016-07-14
AU2015324241A1 (en) 2017-05-18
KR20210088010A (ko) 2021-07-13
US9321994B1 (en) 2016-04-26
AU2021201433C1 (en) 2023-10-05
AU2021201433A1 (en) 2021-03-25
CA3210154A1 (en) 2016-04-07
KR102342470B1 (ko) 2021-12-24
MX2017004288A (es) 2017-10-23
KR20210121290A (ko) 2021-10-07
KR102163403B1 (ko) 2020-10-08
WO2016053758A1 (en) 2016-04-07
CA3000334C (en) 2025-10-07
KR102576875B1 (ko) 2023-09-08
KR102636786B1 (ko) 2024-02-14
KR20230132621A (ko) 2023-09-15
EP3201318B1 (en) 2023-07-26
EP4234032A3 (en) 2023-09-27
JP7672867B2 (ja) 2025-05-08
EP3201318A4 (en) 2018-05-30
KR102316952B1 (ko) 2021-10-25
JP2023109837A (ja) 2023-08-08
US20190002823A1 (en) 2019-01-03
KR20210156353A (ko) 2021-12-24
RU2017114574A (ru) 2018-11-07
US20160194602A1 (en) 2016-07-07
KR102275640B1 (ko) 2021-07-08
KR20170084042A (ko) 2017-07-19
JP2025131663A (ja) 2025-09-09
EP3201318A1 (en) 2017-08-09
US20210062140A1 (en) 2021-03-04
AU2015324241B2 (en) 2021-01-21
ES2961691T3 (es) 2024-03-13
KR20220130833A (ko) 2022-09-27
CN107002029A (zh) 2017-08-01
KR102542748B1 (ko) 2023-06-14
JP6890538B2 (ja) 2021-06-18
AU2021201433B2 (en) 2023-03-16
US11046929B2 (en) 2021-06-29
JP7773502B2 (ja) 2025-11-19
CA3000334A1 (en) 2016-04-07
AU2025238026A1 (en) 2025-10-16
KR102766202B1 (ko) 2025-02-10
KR102445071B1 (ko) 2022-09-19
KR20200068758A (ko) 2020-06-15
JP2017531425A (ja) 2017-10-26
EP4234032A2 (en) 2023-08-30
JP2021113205A (ja) 2021-08-05
KR20230091185A (ko) 2023-06-22

Similar Documents

Publication Publication Date Title
US11046929B2 (en) Induction medium and methods for stem cell culture and therapy
JP6883070B2 (ja) 細胞治療に対する臨床反応を決定するためのリンパ球バイオマーカー
EP2491115B1 (en) Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
HK40019421A (en) Lymphocyte biomarkers for determining the clinical response to cell therapy

Legal Events

Date Code Title Description
AS Assignment

Owner name: WIBIWORKS THERAPEUTICS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BETANCOURT, ALINE;REEL/FRAME:036571/0673

Effective date: 20150903

AS Assignment

Owner name: COMMENCE BIO, INC., MARYLAND

Free format text: CHANGE OF NAME;ASSIGNOR:WIBIWORKS THERAPEUTICS, INC.;REEL/FRAME:037406/0085

Effective date: 20150916

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: SANBIO, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:COMMENCE BIO, INC.;REEL/FRAME:046901/0967

Effective date: 20180914